menu

Recognizing & Treating Alpha-1 Antitrypsin Deficiency (AATD)

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Recognizing & Treating Alpha-1 Antitrypsin Deficiency (AATD)

close
1.00 credits
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Alpha-1 antitrypsin deficiency (AATD) is a common yet underdiagnosed genetic disorder. Led by 2 AATD experts, this activity will address the most current information on the screening, diagnosis, and treatment of this potentially fatal disorder. AATD primarily affects the lungs and liver and requires a multidisciplinary care approach. Faculty will review patients who are at risk for AATD, its clinical manifestations (including similarities with COPD), and possible consequences to the lung and liver. Current treatment involves augmentation therapy with IV administration of AAT; there are ongoing investigations into other potential treatments. Patient cases will help clinicians apply the foundational information to clinical practice.

  • Disclosure of Conflicts of Interest

    Disclosure
    It is the policy of AKH and ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH and ATS prior to accreditation of the activity. AKH and ATS planners and reviewers have no relevant financial relationships to disclose.

    Charlie Strange, MD has disclosed the following relevant financial relationships:
    Advisory Committee non-promotional - Takeda, Vertex
    Advisory Committee promotional - GlaxoSmithKline
    Consultant - AstraZeneca, Dicerna
    Employment - AlphaNet (a non-profit health management corp.)
    Research - AHRQ, CSL Behring, Department of Defense, National Institute of Health,
    Research industry initiated - Adverum, CSA Medical, Grifols, Matrx, Nuvaira, Takeda, Vertex
    Royalties - UpToDate
    Speaker/faculty non-promotional - Medical Education Resources

    Cheryl Pirozzi, MD, MS has no financial relationships to disclose.

    AKH Staff and Planners
    Lynne Kolton Schneider, PhD, Medical Writer/Interviewer: has no financial relationships to disclose.
    Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner: has no financial relationships to disclose.
    Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has no financial relationships to disclose.
    Patricia Brignoni, AKH Director of Operations: has no financial relationships to disclose.
    Steve Eckert, AKH President & CEO, Planner: has no financial relationships to disclose.

    ATS Staff
    Suzette Machado, MPA, CHCP, Associate Director of Education Programs and Accreditation; has no financial relationships to disclose

  • Target Audience

    This activity is designed to meet the educational needs of primary care physicians, pulmonologists, hepatologists, general gastroenterologists, PAs, nurse practitioners, nurses and respiratory therapists.

  • Learning Objectives

    Upon completion of the educational activity, participants should be able to:

    • Explain the pathogenesis of A1A/AATD and its effect on lungs and liver.
    • Implement screening and guideline-concordant diagnostic testing in patients at risk for or suspected of having AATD.
    • Develop individualized evidence-based treatment plans for augmentation therapy in patients diagnosed with AATD and COPD.
    • Develop individualized screening, diagnostic and management plans regarding AATD.
  • Accreditation and Credit Designation Statements

    ReachMD Healthcare ImageCME Credit provided by The American Thoracic Society

    Physicians
    CME Accreditation Statement and Credit Designation
    The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    The American Thoracic Society designates this enduring material activity for a maximum of 1 AMA PRA Category 1 Credits ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    Physician Assistants
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

    ReachMD Healthcare ImageCE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

    Nurse Practitioners

    ReachMD Healthcare ImageAKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030083.
    This activity is approved for 1 contact hour(s) (which includes 0 hour(s) of pharmacology).

    Criteria for Success
    Statements of credit will be awarded based on the participant's attendance, participation in the pre/post-test and submission of the activity evaluation form. A passing score of 70% on the quiz is required to receive credit. A certificate will be available in your transcripts upon successful completion of the quiz and evaluation. If you have questions about this CME/CE activity, please contact AKH Inc. at tbrignoni@akhcme.com. There is no fee for this activity.

    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. ATS and AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare ImageReachMD Healthcare Image

  • Commercial Support

    Supported by an educational grant from Takeda Pharmaceuticals U.S.A, Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Alpha-1 antitrypsin deficiency (AATD) is a common yet underdiagnosed genetic disorder. Led by 2 AATD experts, this activity will address the most current information on the screening, diagnosis, and treatment of this potentially fatal disorder. AATD primarily affects the lungs and liver and requires a multidisciplinary care approach. Faculty will review patients who are at risk for AATD, its clinical manifestations (including similarities with COPD), and possible consequences to the lung and liver. Current treatment involves augmentation therapy with IV administration of AAT; there are ongoing investigations into other potential treatments. Patient cases will help clinicians apply the foundational information to clinical practice.

  • Disclosure of Conflicts of Interest

    Disclosure
    It is the policy of AKH and ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH and ATS prior to accreditation of the activity. AKH and ATS planners and reviewers have no relevant financial relationships to disclose.

    Charlie Strange, MD has disclosed the following relevant financial relationships:
    Advisory Committee non-promotional - Takeda, Vertex
    Advisory Committee promotional - GlaxoSmithKline
    Consultant - AstraZeneca, Dicerna
    Employment - AlphaNet (a non-profit health management corp.)
    Research - AHRQ, CSL Behring, Department of Defense, National Institute of Health,
    Research industry initiated - Adverum, CSA Medical, Grifols, Matrx, Nuvaira, Takeda, Vertex
    Royalties - UpToDate
    Speaker/faculty non-promotional - Medical Education Resources

    Cheryl Pirozzi, MD, MS has no financial relationships to disclose.

    AKH Staff and Planners
    Lynne Kolton Schneider, PhD, Medical Writer/Interviewer: has no financial relationships to disclose.
    Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner: has no financial relationships to disclose.
    Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has no financial relationships to disclose.
    Patricia Brignoni, AKH Director of Operations: has no financial relationships to disclose.
    Steve Eckert, AKH President & CEO, Planner: has no financial relationships to disclose.

    ATS Staff
    Suzette Machado, MPA, CHCP, Associate Director of Education Programs and Accreditation; has no financial relationships to disclose

  • Target Audience

    This activity is designed to meet the educational needs of primary care physicians, pulmonologists, hepatologists, general gastroenterologists, PAs, nurse practitioners, nurses and respiratory therapists.

  • Learning Objectives

    Upon completion of the educational activity, participants should be able to:

    • Explain the pathogenesis of A1A/AATD and its effect on lungs and liver.
    • Implement screening and guideline-concordant diagnostic testing in patients at risk for or suspected of having AATD.
    • Develop individualized evidence-based treatment plans for augmentation therapy in patients diagnosed with AATD and COPD.
    • Develop individualized screening, diagnostic and management plans regarding AATD.
  • Accreditation and Credit Designation Statements

    ReachMD Healthcare ImageCME Credit provided by The American Thoracic Society

    Physicians
    CME Accreditation Statement and Credit Designation
    The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    The American Thoracic Society designates this enduring material activity for a maximum of 1 AMA PRA Category 1 Credits ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    Physician Assistants
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

    ReachMD Healthcare ImageCE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

    Nurse Practitioners

    ReachMD Healthcare ImageAKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030083.
    This activity is approved for 1 contact hour(s) (which includes 0 hour(s) of pharmacology).

    Criteria for Success
    Statements of credit will be awarded based on the participant's attendance, participation in the pre/post-test and submission of the activity evaluation form. A passing score of 70% on the quiz is required to receive credit. A certificate will be available in your transcripts upon successful completion of the quiz and evaluation. If you have questions about this CME/CE activity, please contact AKH Inc. at tbrignoni@akhcme.com. There is no fee for this activity.

    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. ATS and AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare ImageReachMD Healthcare Image

  • Commercial Support

    Supported by an educational grant from Takeda Pharmaceuticals U.S.A, Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 9/18/21